BLRX

BioLineRx Ltd.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$1.35

Price (1 Year)

$3.78 $1.35

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %16.8 / %30
Non-compliant assets / Total market cap %0 / %30
Non-compliant revenue / Total income %72.1 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

Website

Analysis (Turkish): BLRX Hissesi Caiz mi, Helal mi? BioLineRx Ltd. Katılım Analizi